タナカ ジユンジ
TANAKA Junji
田中 淳司 所属 その他 その他 職種 非常勤嘱託 |
|
論文種別 | 総説 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies. |
掲載誌名 | 正式名:Hematological oncology 略 称:Hematol Oncol ISSNコード:10991069/02780232 |
掲載区分 | 国外 |
巻・号・頁 | 39(1),pp.11-19 |
著者・共著者 | Tanaka Junji†* |
担当区分 | 筆頭著者,責任著者 |
発行年月 | 2021/02 |
概要 | Natural killer (NK) cells have a potent cytotoxic activity against leukemia and lymphoma without recognition of human leukocyte antigen (HLA) molecules. Chimeric antigen receptor-engineered NK cells (CAR-NK cells) can be produced from the NK92 cell line, peripheral blood, cord blood, and induced pluripotent stem cells for immunotherapy of malignant tumor cells. Recently, the safety and efficacy of HLA-mismatched allogeneic cord blood-derived CD19 CAR-NK cell therapy for CD19-positive hematological malignancies have been reported. However, the durability of clinical effects has not been clarified. The characteristics of CAR-NK cells with a strong antileukemia/lymphoma effect and better proliferative capacity without severe adverse effects may be promising for overcoming intractable hematological malignancies as an off-the-shelf allogeneic cellular therapy. |
DOI | 10.1002/hon.2802 |
PMID | 32905618 |